JPMorgan reinstated coverage of Immunocore with an Overweight rating and $60 price target. The analyst reinstated ratings, estimates and price targets for the U.S. large cap biotechnology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMCR:
- Immunocore price target lowered to $72 from $74 at Mizuho
- Immunocore reports Q3 EPS 4c, consensus (33c)
- Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
- Roku upgraded, Amazon initiated: Wall Street’s top analyst calls
- Immunocore initiated with an Overweight at Cantor Fitzgerald
